Clinical Trial Update: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This update reports results from a phase 2 study of the BTK inhibitor ibrutinib in participants with relapsed or refractory mantle cell lymphoma, which has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Lymphoma, Mantle-cell | Phase 2 | Status: COMPLETED